Serkan C.

A major focus is on genotype‑driven therapies targeting alterations such as KRAS G12C, ALK, EGFR, ROS1 and BRAF V600E in thoracic malignancies.

• KRAS G12C inhibitor development
• Combination strategies for ALK‑positive lung cancer
• Therapies for ROS1‑rearranged NSCLC
• Targeted approaches for BRAF‑mutant NSCLC

The work supports precision oncology by integrating molecular diagnostics with novel agents.

Beyond oncology, the investigator addresses chronic airway disorders, including chronic obstructive pulmonary disease and severe allergic asthma, as well as viral respiratory infections such as respiratory syncytial virus.

• Reduction of COPD exacerbations
• Optimized Omalizumab regimens for severe asthma
• Maternal RSV vaccination strategies
• Infant RSV prophylaxis with monoclonal antibodies

These studies target reduction of acute events and enhancement of long‑term pulmonary function.

In the neurovascular unit, the investigator explores cognitive and psychotic manifestations of Alzheimer’s disease, particularly hallucinations and delusions.

• Treatment of Alzheimer’s disease psychosis
• Cognitive impairment improvement with novel agents
• Evaluation of KarXT in Alzheimer’s patients
• NPI‑C based assessment of hallucinations

The aim is to alleviate neuropsychiatric burden and preserve functional independence.

Additional interests include acute cerebrovascular injury such as intracerebral haemorrhage and renal immune disorders like minimal change nephrotic syndrome.

• Prophylactic antiseizure therapy after ICH
• Rituximab for relapse prevention in nephrotic syndrome
• Functional outcome improvement post‑ICH
• Immunomodulatory strategies in nephrotic disease

These projects seek to improve acute management and prevent disease recurrence.